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Abstract
Background: Although atrial fibrillation (AF) ablation is considered a technically chal-
lenging procedure, studies on the learning curve of different pulmonary vein isolation (PVI) 
techniques are limited. We investigated the time-dependent changes in procedural parameters, 
complication rates, and in the 1-year clinical outcome during our initial experience with cir-
cular multipolar phased radiofrequency (RF) ablation.
Methods and results: The first 132 consecutive patients (40 female; age: 56.6 ± 10.4 years) 
who underwent PVI with phased RF ablation for paroxysmal or persistent AF at our center 
were included in the study. Procedural parameters and atrial arrhythmia-free survival were 
compared in the first, second and third group of 44 successive patients. All pulmonary veins 
were successfully isolated in 44 (100%), 41 (93.8%) and 42 (95.5%) patients in Tierce 1,  
2 and 3, respectively (p = 0.233). The number of RF applications (per vein) required for isola-
tion and fluoroscopy times demonstrated a significant decrease with experience, and a trend 
towards lower procedure times in Tierces 2 and 3 was also observed. Atrial arrhythmia-free 
survival rates at 12 months postablation were 68.18%, 75%, and 70.75% in Tierce 1, Tierce 2 
and Tierce 3, respectively (p = 0.772). Pericardial tamponade requiring percutaneous subxi-
phoid drainage occurred in 1 patient (Tierce 3) as the only significant procedural complication.
Conclusions: A learning curve effect was demonstrated in fluoroscopy times and in the 
number of RF applications but not in the acute success and in the long-term arrhythmia-free 
survival with circular multipolar RF ablations. (Cardiol J 2015; 22, 3: 260–266)
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Introduction
Catheter ablation for atrial fibrillation (AF) 
has emerged as an alternative to antiarrhythmic 
drug (AAD) therapy after the failure of at least 
one AAD, or even as the first line of treatment in 
selected cases [1–3]. Although a wide variety of 
ablation techniques have been used to treat AF, 
it is generally agreed that the cornerstone of any 
transcatheter procedure is the electrical isolation 
of all pulmonary veins (PVs). This is currently most 
commonly achieved by encircling the PVs with focal 
radiofrequency (RF) lesions under the guidance 
of a 3-dimensional electroanatomical mapping or 
navigation system. This point-by-point ablation 
technique requires extensive operator experience 
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for efficiency and safety, and is usually associated 
with long procedure times. Novel methods aiming at 
simpler and faster PV isolation (PVI) have therefore 
been developed in recent years, including cryobal-
loon ablation (CBA) [4, 5] and multipolar RF ablation 
with the circular PV ablation catheter (PVAC) [6–9]. 
These “single-shot” techniques were designed to 
create a circular ablation lesion around the PVs after 
the appropriate positioning of the ablation catheter 
at the ostium or at the antra of each PV. A number 
of studies have demonstrated comparable levels of 
success and safety profile, but shorter procedure 
times with these simplified methods than with the 
conventional point-by-point ablation [10–13].
With the continuous increase in the number 
of AF ablation worldwide, the procedure is being 
introduced into new and less experienced cent-
ers. Efficacy and periprocedural complications 
are known to improve with experience in every 
invasive procedure including AF ablation although 
the learning curve effect has not been extensively 
evaluated. Sairaku et al. [14] have reported a sig-
nificantly higher incidence of procedure-related 
complications and a lower arrhythmia-free survival 
at 6-month follow-up with double Lasso catheter-
guided encircling PVI in the first 52 as compared 
with the following 156 patients who underwent 
the ablation. Wójcik et al. [15] have demonstrated 
a learning curve effect with CBA as indicated by the 
decline in procedure and fluoroscopy times. How-
ever, improvement in the long-term outcome over 
time has been attributed to a more careful patient 
selection and not to operator experience per se.
We have now investigated the time-dependent 
changes in procedural parameters, complication 
rates, and in the 1-year clinical outcome during our 
initial experience with phased RF ablation.
Methods
Study population
The present study included consecutive pa-
tients who underwent PVI with phased RF abla-
tion for paroxysmal or persistent AF at our center 
between November 01, 2009 and April 30, 2012, 
and who had regular follow-up during the first 
12 months post-ablation. Exclusion criteria included 
previous AF ablation, long-standing persistent AF, 
hyper- and hypothyroidism, significant valvular 
heart disease, heart failure of New York Heart 
Association class III or IV, a left ventricular ejec-
tion fraction ≤ 40%, a left atrial (LA) diameter 
exceeding 50 mm, a LA thrombus, unstable angina 
or myocardial infarction within the last 3 months, 
severe chronic obstructive pulmonary disease, 
known bleeding disorders, contraindication to oral 
anticoagulation, and pregnancy. All participating 
patients signed the informed consent form prior 
to the procedure.
Patient preparation and pre-procedural 
evaluation
Patients were admitted to the hospital 1 or 
2 days prior to the procedure. Those on oral an-
ticoagulation with a vitamin K antagonist (VKA) 
continued to take the drug and the procedure was 
performed with an international normalized ratio 
in the therapeutic range. For all other patients, 
low molecular weight heparin was admnistered 
twice daily in a weight-adjusted dose and until 12 h 
prior to the procedure. All patients scheduled 
for ablation were examined by transesophageal 
echocardiography within 24 h to rule out an intra-
cardiac thrombus. The LA and PV anatomies were 
assessed by means of multislice cardiac computed 
tomography imaging before the ablation.
Ablation procedure with phased RF  
and the PVAC
Ablation procedures were performed under 
conscious sedation with midazolam and fentanyl. 
Decapolar (BARD Electrophysiology Inc., Lowell, 
MA, USA) and quadripolar (Woxx 4 J, 6F, Biotronik, 
SE & Co. KG, Berlin, Germany) catheters were 
advanced from the femoral vein and positioned into 
the coronary sinus and the right ventricle. Surface 
electrocardiograms (ECG) and bipolar intracardiac 
electrograms were registered with a Prucka, GE 
Medical digital recording system. A single trans-
septal puncture was performed under fluoroscopic 
guidance, by a standard technique using a Swartz 
SL (St. Jude Medical, Minneapolis, Mn, USA) trans-
septal sheath. This sheath was then exchanged for 
a deflectable 12 Fr CryoCath sheath (Medtronic 
CryoCath LP, Kirkland, Quebec, Canada) to be 
used for guiding in LA under continuous flush with 
heparinized saline. Immediately after the transsep-
tal puncture, a 150 IU/kg body weight intravenous 
(i.v.) heparin bolus was administered, followed by 
a continuous infusion to maintain a minimum activa-
ted clotting time (ACT) target level of > 300 s during 
ablations. Additional i.v. boluses of 2,000–5,000 IU 
heparin were administered as needed to attain the 
minimum target ACT level. This heparinization 
scheme was the same regardless of the ongoing 
rhythm (sinus rhythm vs. AF) during ablation.
The technical specifications of the circu-
lar multipolar PVAC, the GENius RF generator 
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(Medtronic Inc., Minneapolis, MN, USA) and 
the methodology used in our center have been 
described in detail [16, 17]. Briefly, the catheter 
was advanced through the FlexCath sheath over 
a 0.032-inch guide wire (BARD Electrophysiology 
Inc., Lowell, MA, USA), which was positioned 
selectively in each PV. The electrical conduction 
properties of the PV were assessed on the basis 
of the signals recorded by the PVAC electrodes 
after placement inside the ostium. Before the 
first RF delivery, the positions of the electrodes 
relative to the PV ostium were always confirmed 
by means of selective contrast injection through 
the FlexCath sheath. Care was taken to always 
apply the RF outside the vein in the antral region, 
targeting potentials of high amplitude on as many 
electrodes as possible for each application. Com-
mon ostia were isolated by inserting the guide 
wire into the different side branches and ablating 
subsequent segments of the targeted veins. The 
PVAC was connected to the GENius RF generator, 
which is capable of delivering RF current in dif-
ferent bipolar/unipolar mode ratios to any or all of 
the 5 bipolar channels in a duty-cycled mode. The 
target temperature was 60oC, measured separately 
for all bipoles. Bipolar/unipolar RF delivery was 
usually started at a ratio of 4:1 for each PV and 
changed to a bipolar/unipolar proportion of 2:1 for 
a deeper lesion when a sufficient reduction in local 
electrogram amplitude could not be achieved after 
multiple RF deliveries. RF energy was applied 
for 60 s, usually 3–4 times per PV, until PVI was 
achieved. The PV conduction was reassessed after 
each RF application, the electrodes being advanced 
inside the ostium.
Follow-up
Patients were usually discharged within 
2 days after the ablation. Following the procedure 
a VKA was continued for at least 3 months. Pa-
tients taking an AAD before the procedure con-
tinued the medication for 3 months post-ablation. 
It was then discontinued if the patient was free of 
an AF relapse. VKA was discontinued 3 months 
after the ablation only in patients with a CHA2DS2-
-VASc (Congestive heart failure, Hypertension, 
Diabetes mellitus, age > 75 years; prior stroke or 
transient ischemic attack, Vascular disease, Age 
65–74, female gender) score of 1 or below, while 
those patients with a higher stroke risk were kept 
on oral anticoagulation regardless of the results 
of postablation arrhythmia monitoring. Follow-up 
visits were scheduled at 6 weeks, and 3, 6, 9 and 
12 months post-procedure.
The 12-lead ECG was checked at each follow-
-up. Additionally, 24-h Holter monitoring was 
performed at least twice, and also transtelephonic 
monitoring 3 times for 14–21 days, during the first 
6 months. Patients were asked to transmit their 
rhythm at least 2–3 times a day, and always in the 
event of any palpitation. During non-telemetry 
periods of follow-up, patients were encouraged 
to visit the nearest hospital or outpatient facility 
to document their rhythm on an ECG whenever 
they felt any abnormality of their heart beat. Ar-
rhythmia recurrence was defined as any atrial ar-
rhythmia lasting for 30 s or longer. The definition 
of long-term success was freedom from any atrial 
arrhythmia without any AAD, after 1 procedure 
with a blanking period in the first 3 months.
End points
The acute endpoint of the procedure was the 
electrical isolation of all PVs, as confirmed by an 
entrance block.
Long-term efficacy was defined as freedom 
from any atrial arrhythmia without a Class I or 
Class III AAD after 1 procedure at 12-month follow-
-up with a blanking period in the first 3 months.
Significant periprocedural complications were 
defined as any injury which resulted in death or had 
long-term sequel, requiring an immediate interven-
tion or prolonged hospital stay.
Statistical analysis
The study period was divided into tierces to in-
clude the same number of patients who underwent 
AF ablation within each tierce. Clinical character-
istics, procedural and follow-up data for subjects 
in each tierce were presented using numbers and 
frequencies (%) for categorical variables and means 
with standard deviations for continuous variables. 
Statistical calculations were performed with IBM 
SPSS Statistics 20 Software.
The distribution was examined with Kolmog-
orov-Smirnov test. Discrete variables were ana-
lyzed using c2 test. ANOVA (analysis of variances) 
and Kruskal-Wallis were used for comparisons of 
groups. Cox regression as univariate test was used 
to estimate the hazard ratio. P value less than 0.05 
was considered significant.
Results
A total of 132 patients were enrolled. Preab-
lation clinical characteristics of the first, second 
and third group of 44 patients who underwent PVI 
with phased RF ablation are displayed in Table 1. 
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Significant differences between the three tierces 
were found in the age and in the LA size only.
A total of 177 PVs were successfully isolated out 
of the 177 targeted in Tierce 1, while 173/176 and 
169/171 in Tierces 2 and 3, respectively (p > 0.05).
All PVs were successfully isolated in 44 (100%), 
41 (93.8 %) and 42 (95.5 %) patients in Tierce 1, 
2 and 3, respectively (p = 0.233). However, the 
number of RF applications (per PV) needed for 
isolation demonstrated a significant decrease with 
experience (6.22 ± 2.43; 4.65 ± 1.32 and 4.12 ± 
± 1.2 in Tierce 1, 2 and 3, respectively; p < 0.001). 
Procedure times demonstrated a trend towards 
lower values in Tierces 2 and 3 but the difference 
did not reach the level of statistical significance. 
In contrast, a significant decrease in fluoroscopy 
times was demonstrated (Fig. 1).
Pericardial tamponade requiring percutaneous 
subxiphoid drainage occurred in the 104th con-
secutive patient (Tierce 3) as the only significant 
procedural complication.
Atrial arrhythmia-free survival rates without 
AAD at 12 months postablation were 68%, 75%, 
and 70.75% in Tierce 1, Tierce 2 and Tierce 3, re-
spectively (p = 0.772). In Cox proportional hazard 
analysis which included clinical and procedural 
variables no significant predictor of arrhythmia 
recurrence was demonstrated (Table 2).
Discussion
Main findings
This study assessed the effects of learning 
curve on procedural parameters and long-term 
success during phased RF ablation with the PVAC. 
Fluoroscopy time and the number of RF applica-
tions required for successful PVI declined progres-
sively with more experience, and a similar trend 
was observed for procedure time. Importantly, 
no learning curve effect was demonstrated in the 
success and complication rates.
Previous studies on learning curve  
in AF ablation
Although AF ablation is considered technically 
more challenging compared with other ablation 
procedures, very limited data have been published 
on the significance of operator experience in rela-
tion to the safety and efficacy of the procedure. 
The first study that specifically addressed the 
importance of the learning curve during AF abla-
tion was published by Sairaku [14] who reported 
on the results of the first 208 consecutive PVIs 
with point-by-point focal RF ablation in a medium-
volume center. A significant learning curve effect 
has not only been demonstrated in procedure and 
fluoroscopy times, but also in complication rates 
and in the arrhythmia-free survival at 6-month 
follow-up. In another study summarizing the ex-
perience, on 641 AF ablations at Johns Hopkins 
Table 1. Baseline clinical characteristics in each tierce.
Patient characteristics Tierce 1 Tierce 2 Tierce 3 P
Age 55.12 ± 10.13 54.85 ± 10 59.82 ± 10.45 0.04
Male/female 33/11 31/13 28/16 0.506
Type of atrial fibrillation: persistent 10 (22.72%) 9 (20.45%) 3 (6.82%) 0.096
Medical history:
Hypertension 31 (70.45%) 29 (65.9%) 36 (81.8%) 0.225
Diabetes 5 (11.36%) 8 (18.18%) 7 (15.9%) 0.662
Coronary artery disease 4 (9.1%) 6 (13.63%) 9 (20.45%) 0.311
Left atrial diameter [mm] 40.61 ± 4.6 43.16 ± 4.98 42.11 ± 4.35 0.039
Left ventricular ejection fraction [%] 55.45 ± 6.1 54.52 ± 7.69 55.43 ± 7.95 0.792
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Figure 1. Procedure and fluoroscopy times in each 
tierce.
Hospital complication rates were 9% during the 
first 100 and 4.3% during the subsequent 541 pro-
cedures [18]. A worldwide survey [19] and the most 
recent consensus statement on AF ablation [1] also 
suggest that safety and efficacy results are better 
in centers performing more than 100 procedures 
annually. These recommendations are largely based 
on the experience gained with focal RF ablation.
Single-shot AF ablation techniques have been 
introduced to simplify and speed up PVI proce-
dures. Available data on the the influence of opera-
tor experience as related to the safety and efficacy 
results with these simplified approaches are also 
limited. Wójcik et al. [15] reported on the proce-
dural experience gained over 8 years with CBA in 
a high-volume center. A continuous decrease in 
fluoroscopy and procedure times was observed in 
each subsequent year and in multivariate analysis 
both the year of procedure and the preablation 
ALARMEc (Atrial fibrillation type, LA size, Renal 
insufficiency, MEtabolic syndrome, cardiomyo-
pathy) risk score were independent predictors 
of procedure and fluoroscopy times. However, 
no significant decrease in complication rate over 
the 8-year period has been demonstrated. The 
overall success rate at 12 months postablation was 
73%, which improved with each subsequent year, 
however this was related to the gradual fall in the 
ALARMEc risk score. In another single center 
study, the learning curves for PVI with phased RF 
ablation vs. with the cardiofocus laser balloon have 
been compared in the first 50 patients undergoing 
PVI with each technology [20]. Procedure and 
fluoroscopy times decreased with time in both tech-
nologies. Atrial arrhythmia recurrence 6 months 
after a single procedure improved significantly from 
the first tierce (31.2%) to the second (17.6%) and 
to the third (0%) with cardiofocus laser balloon 
but no clear improvement was found with phased 
RF ablation.
These published data are in line with our 
results and suggest that the influence of opera-
tor experience on clinical success and procedural 
complications of AF ablation may be less significant 
with a single-shot as compared with the conven-
tional method. This is further supported by the 
initial experience of a center with AF ablation [21]. 
The first 109 patients at this center underwent PVI 
with either 3-dimensional guided focal RF or with 
phased RF ablation. The 6-month success rate was 
significantly higher with phased RF (68%) as com-
pared with focal (39%) ablation, while complication 
rates were similar. Procedure and fluoroscopy 
times were also significantly shorter with phased 
RF ablation.
Although studies on direct comparison of 
PVAC with point-by-point PVI are limited, similar 
success rates have recently been reported with 
the two techniques [22]. In a multicenter prospec-
tive randomized comparison, the arrhythmia-free 
survival at 12 months was 56% with wide-area 
circumferential ablation and 60% with phased 
RF ablation in patients with paroxysmal AF. The 
efficacy of PVI with the PVAC without any other 
Table 2. Cox regression analysis on 12-month arrhythmia-free survival.
Variable Hazard ratio AF free survival
95% confidence interval
P
Gender 1.352 0.589–3.106 0.477
Age 1.019 0.978–1.061 0.376
Persistent AF 1.291 0.542–3.078 0.564
Hypertension 0.970 0.390–2.409 0.947
Coronary artery disease 1.266 0.467–3.437 0.643
Diabetes 0.808 0.301–2.165 0.671
Left atrial diameter 1.001 0.925–1.083 0.985
Left ventricular ejection fraction 0.988 0.940–1.038 0.629
Total procedure time 0.996 0.987–1.005 0.372
Fluoroscopy time 1.026 0.986–1.068 0.207
Group I 0.839
Group II 0.777 0.337–1.793 0.555
Group III 0.898 0.383–2.106 0.805
AF — atrial fibrillation
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LA ablation target in more chronic forms of AF is 
yet to be determined [23]. Although the TTOP-AF 
study evaluated phased RF ablation in such pa-
tient cohort, other ablation catheters (multi-array 
ablation catheter and multi-array septal catheter) 
to target low amplitude high frequency complex 
fractionated electrograms on the LA posterior 
wall and septum were also used in that study. The 
ongoing Victory-AF trial is currently enrolling pa-
tients with persistent and long-standing persistent 
AF using PVAC GOLD the new generation of the 
PVAC catheter [24].
Potential implications for clinical practice
Available data suggest that the learning curve 
in PVI and the influence of previous operator experi-
ence on relevant procedural and clinical endpoints 
might be ablation technology-dependent. Ablation 
with a single-shot device can be performed not only 
with shorter procedure and fluoroscopy times as 
compared with focal ablation, but also with more 
satisfactory clinical outcome by a well-trained 
electrophysiologist who is proficient in transseptal 
catheterization and LA ablation but is in the early 
phase of his AF ablation practice. Further, any of 
these simplified approaches might be a reasonable 
choice for lower volume centers as a regular perfor-
mance of a higher number of procedures is required 
not only to develop but also to maintain the adequate 
technical skills with point-by-point ablation.
Limitations of the study
This study has several limitations. First, 
this was a single center, observational patient 
cohort study including a relatively small number 
of patients thereby limiting the statistical power. 
There was, however, no selection bias for the study 
as consecutive patients undergoing AF ablation 
with phased RF were enrolled. Second, the main 
operator in all procedures had gained previous, 
although limited experience with CBA before 
he started this study, which required somewhat 
similar skills as ablation with the PVAC, therefore 
these results may not necessarily apply to what 
could be achieved by someone with absolutely no 
experience in AF ablation. Third, although high 
incidence of new silent cerebral ischemia detected 
by diffusion-weighted magnetic resonance imaging 
was reported after phased RF ablations [25, 26], 
this subclinical complication was not assessed in 
this study. However, most recent data indicated 
a very substantial reduction in silent cerebral em-
bolization thanks to some technical and procedural 
modifications in phased RF ablation [27, 28].
Conclusions
This study investigated the time-dependent 
changes in procedural parameters, complication 
rates, and in the 1-year clinical outcome during our 
initial experience with circular, multipolar phased 
RF ablation. A learning curve effect was demon-
strated in fluoroscopy times and in the number of 
RF applications but not in the acute success and in 
the long-term arrhythmia-free survival.
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